Chemical formula: C₆H₁₂N₂Na₅O₁₂P₄Sm Molecular mass: 586.021 g/mol PubChem compound: 76962714
Samarium has an affinity for skeletal tissue and concentrates in areas of bone turnover in intimate association with hydroxyapatite. It is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium (99mTc)-labelled biphosphonates on bone scan.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V10BX02 | Samarium (153Sm) lexidronam | V Various → V10 Therapeutic radiopharmaceuticals → V10B Pain palliation (bone seeking agents) → V10BX Various pain palliation radiopharmaceuticals |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| QUADRAMET Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Samarium ¹⁵³Sm lexidronam is an active ingredient of these brands:
United States (US)Austria (AT)Croatia (HR)Estonia (EE)France (FR)Ireland (IE)Italy (IT)Lithuania (LT)Poland (PL)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
